Medication info
Omeprazole 20 mg (Esomeprazole Magnesium Trihydrate)

Omeprazole 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Vibocog Pharmaceutical Co., Ltd.
Appearance
Pale pink, round, film-coated tablets
Packaging
28 tablets/box [14 tablets/Alu-Alu X 2], 28 tablets/box [7 tablets/Alu-Alu X 4]
Approval status
Active

MFDS item code 201507071 · Approved 2015.10.08 · Insurance code 658202930

Summary

Main use
Acid-related disorders (reflux, etc.), ulcers, eradication, and rebleeding; treatment and prevention of NSAID-induced gastrointestinal disorders
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent symptoms are controlled by administering 20 mg once daily. In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling subsequent symptoms in patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug administration. Combination antibiotic therapy for Helicobacter pylori eradication: Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. Patients requiring continued administration of nonsteroidal anti-inflammatory drugs Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug administration: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug administration: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration: Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal failure. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Older adults: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Vibocog Pharmaceutical Co., Ltd.

Efficacy & effects

Acid-related disorders (reflux, etc.), ulcers, eradication, and rebleeding; treatment and prevention of NSAID-induced gastrointestinal disorders

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • symptoms of gastroesophageal reflux disease without esophagitis
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers related to non-steroidal anti-inflammatory drug use
  • duodenal ulcers related to non-steroidal anti-inflammatory drug use
  • Zollinger-Ellison syndrome
View approved original text

This medication is used not only to treat gastroesophageal reflux disease and erosive esophagitis but also for long-term maintenance therapy to prevent recurrence in patients with esophagitis. Additionally, it is effective in alleviating symptoms of gastroesophageal reflux disease without esophagitis. As part of the antibiotic combination therapy to eradicate Helicobacter pylori infection, it is also utilized to prevent recurrence in patients with Helicobacter pylori positive duodenal and peptic ulcers. It provides short-term treatment for pain or discomfort in the upper gastrointestinal tract caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs) and aids in the treatment of gastric ulcers and prevention of gastric and duodenal ulcers in patients requiring continuous NSAID therapy. Furthermore, it is used in the treatment of Zollinger-Ellison syndrome and maintenance therapy after initiating prevention against rebleeding of gastric or duodenal ulcers. Overall, it is utilized effectively to treat and prevent various gastrointestinal-related diseases and symptoms.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent symptoms are controlled by administering 20 mg once daily. In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling subsequent symptoms in patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug administration. Combination antibiotic therapy for Helicobacter pylori eradication: Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. Patients requiring continued administration of nonsteroidal anti-inflammatory drugs Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug administration: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug administration: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration: Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal failure. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Older adults: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent symptoms are controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. First, patients who are allergic to this drug or have a history of hypersensitivity reactions should not take it. Second, patients who have hypersensitivity to penicillin or macrolide antibiotics among the antibiotics combined for eradication of Helicobacter pylori should also avoid this medication. Third, patients taking certain heart-related medications, antiviral drugs, and breastfeeding women should not take this medication. This drug contains the pigment Yellow No. 5, so those with allergies or hypersensitivity to this component should use it cautiously. Various adverse reactions may occur during treatment. For instance, blood cell count reduction, allergic reactions, electrolyte imbalance, headache, dizziness, gastrointestinal symptoms, skin rash, muscle pain, etc., have been reported. Rarely, serious skin disorders or liver function impairment may also occur, so consult a doctor immediately if symptoms arise. This medication suppresses gastric acid secretion, which may promote bacterial growth in the gastrointestinal tract, slightly increasing the risk of infections such as diarrhea. Furthermore, long-term use may increase the risk of fractures, so patients at risk for osteoporosis require regular check-ups. This medication can interact with several drugs, so inform your doctor or pharmacist if you are taking other medications. Caution is especially needed when used with anticoagulants, antiviral drugs, certain antibiotics, and anticonvulsants. Its safety during pregnancy has not been fully established, so it should be administered cautiously under a doctor's judgment, and it is advisable that breastfeeding women do not take it. In case of overdose, no specific antidote exists, so appropriate treatment should be provided according to symptoms, and keep it out of the reach of children. It is important to avoid transferring the medication to another container as it may not be good for maintaining quality.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, malaise, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, general edema, leg edema, lethargy, pain, rigidity, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, worsening of arthritis, arthropathy, cramps, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disturbances, tremors, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered olfaction, loss of taste, taste disorder, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, discoid lupus erythematosus, gastric adenomatous polyp, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, elevated creatine kinase, increase of myoglobin in blood and urine, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container, protected from air and moisture, and kept at a temperature between 1 and 30 degrees Celsius. By storing it this way, the efficacy of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Pale pink, round, film-coated tablets

Package unit

28 tablets/box [14 tablets/Alu-Alu X 2], 28 tablets/box [7 tablets/Alu-Alu X 4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.